What is the FDA pregnancy category of fluconazole (an antifungal medication)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 1, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

FDA Pregnancy Category of Fluconazole

Fluconazole is classified as FDA Pregnancy Category D for most indications, except for single-dose (150mg) treatment of vaginal candidiasis which is classified as Category C. 1

Explanation of FDA Pregnancy Categories

The FDA pregnancy category system classifies medications based on their potential risk to the fetus:

  • Category C: Animal studies have shown adverse effects on the fetus, but there are no adequate studies in humans. Potential benefits may warrant use despite potential risks.
  • Category D: There is positive evidence of human fetal risk, but potential benefits may warrant use despite risks in serious situations.

Evidence Supporting This Classification

High-Dose Fluconazole Risks

  • High-dose fluconazole (≥400 mg daily) has been associated with a pattern of birth defects known as "fluconazole embryopathy" which includes craniosynostosis, characteristic facial abnormalities, digital synostosis, and limb contractures 2, 1
  • Exposure to high-dose fluconazole (>150 mg) during the first trimester is associated with an increased risk of cardiac septal closure anomalies (adjusted OR 1.81) 3

Low-Dose Fluconazole Considerations

  • Single-dose fluconazole (150 mg) for vaginal candidiasis has historically been considered relatively safer, but recent evidence suggests caution is warranted throughout pregnancy 1
  • A 2019 meta-analysis found that oral fluconazole use during the first trimester was associated with an increased risk of heart malformations (OR 1.31) and spontaneous abortion (OR 1.99) 4

Clinical Recommendations

Preferred Alternatives During Pregnancy

  • First-line treatment: Topical azole antifungals (clotrimazole, miconazole) are preferred for vaginal candidiasis during pregnancy due to minimal systemic absorption 1
  • For systemic infections: Amphotericin B is the preferred agent for systemic fungal infections during pregnancy (FDA Category B) 2, 1

If Fluconazole Is Necessary

  • Avoid fluconazole during the first trimester if possible 1
  • For invasive or refractory esophageal candidal infections, substitution of amphotericin B for high-dose fluconazole in the first trimester is recommended 2
  • If fluconazole is required after the first trimester, use the lowest effective dose for the shortest duration possible 1

Important Precautions

  • Women of childbearing potential should use effective contraception while taking fluconazole 1
  • Chemoprophylaxis using systemically absorbed azoles should not be initiated during pregnancy and should be discontinued for HIV-infected women who become pregnant 2
  • For women requiring fluconazole during pregnancy, monitoring for signs of fetal distress and detailed ultrasound evaluation for potential malformations is advised 1

The FDA pregnancy category classification system has been replaced with the Pregnancy and Lactation Labeling Rule (PLLR) for newer medications, but many clinicians still reference the older category system for medications approved before the change.

References

Guideline

Antifungal Treatment During Pregnancy

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Associations between low- and high-dose oral fluconazole and pregnancy outcomes: 3 nested case-control studies.

CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2019

Research

The safety of oral fluconazole during the first trimester of pregnancy: a systematic review and meta-analysis.

BJOG : an international journal of obstetrics and gynaecology, 2019

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.